Edition:
United States

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.26USD
4:00pm EDT
Change (% chg)

$0.03 (+2.23%)
Prev Close
$1.23
Open
$1.23
Day's High
$1.26
Day's Low
$1.22
Volume
89,671
Avg. Vol
71,278
52-wk High
$2.12
52-wk Low
$1.06

Chart for

About

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its... (more)

Overall

Beta: 0.26
Market Cap(Mil.): $138.59
Shares Outstanding(Mil.): 110.87
Dividend: --
Yield (%): --

Financials

  PSTI.OQ Industry Sector
P/E (TTM): -- 235.76 33.88
EPS (TTM): -0.24 -- --
ROI: -66.58 -5.45 13.21
ROE: -70.18 -6.94 15.18

Israel's Pluristem sees positive results from leg pain study

TEL AVIV Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

Jun 12 2018

Israel's Pluristem sees positive results from leg pain study

TEL AVIV, June 12 Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

Jun 12 2018

FDA clears Pluristem radiation treatment for emergency use

HAIFA, Israel Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

Apr 30 2018

FDA clears Pluristem radiation treatment for emergency use

HAIFA, Israel, April 30 Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

Apr 30 2018

BRIEF-U.S. FDA Clears Pluristem’S Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery

* U.S. FDA CLEARS PLURISTEM’S PHASE III STUDY IN TREATMENT OF MUSCLE INJURY FOLLOWING HIP FRACTURE SURGERY

Apr 25 2018

BRIEF-Pluristem Therapeutics Says Co Sold Its Entire Holdings In CHA Biotech Co For About $10.5 Mln

* PLURISTEM THERAPEUTICS - ON JAN 8, CO SOLD ITS ENTIRE HOLDINGS IN CHA BIOTECH CO LTD, CONSISTING OF 400,368 SHARES OF CHA, FOR ABOUT $10.5 MILLION

Jan 09 2018

BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia

* PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO'S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​

Jan 09 2018

Earnings vs. Estimates